FORT WORTH, T.X. (Nov. 3, 2018) – Contact at the front of the field brought out the caution on lap one Saturday afternoon at Texas Motor Speedway. Reed avoided any major damage in the melee, but suffered some cosmetic hood damage that required multiple trips down pit road for bearbond. Reed rebounded from the early contact and by the end of the race was in contention for a solid top-10 finish, until another competitor got underneath him on the track causing the No. 16 Drive Down A1C Lilly Diabetes Ford Mustang to get into the outside wall. The damage was too severe to continue, sending Reed to the garage four laps shy of the scheduled distance and scored with a 29th-place finish.
“We just struggled all day, we tried a lot of stuff and it just didn’t work out the way we wanted it to,” said Reed. “I am really proud of the effort of the guys for sticking with it. All the No. 16 team guys. I couldn’t ask for a better group of guys to work hard and at least try to go for successful runs. Unfortunately the parts and pieces just weren’t there this evening.”
Reed started the 200-lap race 14th, but suffered some minor damage as an incident unfolded in front of him on lap one. The buckled hood required a trip down pit road for bearbond. Despite the setback, Reed was able to drive from the back up to 17th to close out the first 45-lap stage.
Over the course of stage two the bearbond continued to flap around and required multiple pit stops, when timing allowed, to try and secure everything in place. The extra pit stops marred Reed back in the field and at the stage two conclusion on lap 90 he was scored 22nd.
Reed lined up 20th for the final stage and after some track bar and air pressure adjustments the No. 16 was making up lost ground on the track. As the laps dwindled down there were multiple cautions in the field. Reed was able to capitalize and was on his way to a solid top-10 finish when he became a victim of one of the many cautions. The damage sent Reed to the garage four laps shy of the scheduled race distance.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes.
